ADVFN - Advanced Financial Network.
HOME» NASDAQ » M » MYL Stock Price » MYL Stock News

Mylan Inc. Share News

 Mylan Inc. (mm) Stock Price
MYL Stock Price
 Mylan Inc. (mm) Stock Chart
MYL Stock Chart
 Mylan Inc. (mm) Stock News
MYL Stock News
 Mylan Inc. (mm) Company Information
MYL Company Information
 Mylan Inc. (mm) Stock Trades
MYL Stock Trades

US Judge Upholds Validity Of Merck's Vytorin Patent

By Peter Loftus Of DOW JONES NEWSWIRES A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (MRK) Vytorin cholesterol-lowering drug, which could stave off competing generic copies for several years. In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said a patent for Vytorin was valid and enforceable. Merck, based in Whitehouse Station, N.J., said in a recent regulatory filing it expects its U.S. exclusivity for Vytorin and a related drug, Zetia, to expire in April 2017. Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell a generic version of Vytorin before its patent protection expired, arguing that the patent was invalid and unenforceable. Schering-Plough, which was acquired by Merck in 2009, filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's product. A trial was held in December 2011, leading to Judge Linares's opinion Friday. On a conference call with analysts Friday morning, Merck Chief Executive Kenneth Frazier said he was anticipating a favorable decision. "We believe this is a patent that is valid and enforceable," he said. A Mylan spokeswoman couldn't immediately be reached. Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million. Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval. -By Peter Loftus, Dow Jones Newswires; +1-215-982-5581;

Stock News for Mylan Inc. (MYL)
05/27/201518:10:37Teva Reports Small Stake in Mylan
05/27/201517:59:28Teva Reports Small Stake in Mylan
05/26/201516:48:00Mylan to Present at the Bernstein Strategic Decisions Conference
05/25/201509:47:00Mylan/Perrigo Clarification
05/23/201512:03:02Billionaire George Soros Just Sold These 3 Stocks: Should You?
05/23/201509:09:02Will Competition Cause Teva Pharmaceutical Industries ltd. To...
05/21/201517:00:06Law Firm Advising Teva Dismisses Mylan Objections
05/21/201516:55:12Law Firm Advising Teva on Bid Dismisses Mylan's Objections to...
05/20/201512:15:10What Is the S&P 500 Index?
05/12/201516:59:19Perrigo to Buy Patheon's Mexican Business
05/12/201516:56:41Perrigo to Buy Patheon's Mexican Business for $34 Million
05/12/201516:00:00Mylan to Present at the UBS Global Healthcare Conference
05/12/201507:30:00Mylan to Present at the Bank of America Merrill Lynch Health...
05/08/201506:21:19Quarterly Report (10-q)
05/07/201517:25:22Current Report Filing (8-k)
05/07/201511:37:02Why Mylan NVs Mega-Merger Triangle Sent Its Shares Up 22% in...
05/07/201506:30:00Fashion Icon, Chef and Actor Join Together to Share Personal...
05/06/201506:03:54Proxy Statement - Merger or Acquistion (preliminary) (prem14a)
05/05/201517:32:52Securities Registration: Business Combination (s-4)
05/05/201517:22:45Filing of Certain Prospectuses and Communications in Connection...

Mylan Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations